25-Year UK Trends in Cancer Incidence and Mortality

ByHolly Zink
25-Year UK Trends in Cancer Incidence and Mortality

Cancer remains a significant public health challenge worldwide, with its impact extending across generations. A recent study sheds light on the evolving landscape of cancer in the UK over the past 25 years. Their retrospective analysis, focusing on adults aged 35-69, offers valuable insights into cancer trends, highlighting both progress and areas that require continued attention.

Increasing Incidence, Decreasing Mortality

One of the key findings of the study is the notable increase in cancer incidence among adults in the specified age group. The number of cancer cases rose by 57% for men and 48% for women between 1993 and 2018. This increase was primarily driven by rising rates of prostate cancer in men and breast cancer in women. However, when these two cancers were excluded from the analysis, overall cancer trends remained relatively stable.

Despite the increase in cancer incidence, the study also reports a significant decrease in cancer mortality rates over the same period. Cancer deaths decreased by 20% in men and 17% in women. This decline in mortality rates is attributed to advancements in cancer prevention, early detection, diagnostic tools, and treatment options.

Notable Trends in Specific Cancers

While the overall trends are positive, the study highlights concerning increases in the incidence rates of certain less common cancers, such as melanoma skin, liver, oral, and kidney cancers. These findings underscore the need for targeted prevention and early detection strategies for these specific cancer types.

On the other hand, the study reports significant decreases in mortality rates for stomach, mesothelioma, and bladder cancers in men, and stomach, cervical, and non-Hodgkin lymphoma in women. These reductions demonstrate the impact of effective interventions and advancements in cancer care.

Mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs (pleural mesothelioma) or the abdomen (peritoneal mesothelioma). It is caused by exposure to asbestos fibers, with symptoms often not appearing until decades after exposure. Mesothelioma is challenging to diagnose and treat, with a poor prognosis due to its aggressive nature and often late-stage diagnosis.

Treatment options may include surgery, chemotherapy, and radiation therapy, but the effectiveness of these treatments can vary depending on the stage of the cancer and other factors. Ongoing research is focused on developing more effective treatments and improving outcomes for individuals affected by mesothelioma.

Implications for the Future

The findings of this study provide a valuable benchmark for future research and policy development. They underscore the importance of ongoing efforts to prevent, detect, and treat cancer. Additionally, the study serves as a baseline for evaluating the impact of external factors, such as the COVID-19 pandemic, on cancer trends and outcomes in the coming years.

In conclusion, this new study offers a comprehensive analysis of cancer trends in the UK over the past 25 years. While the increase in cancer incidence presents challenges, the significant reduction in mortality rates reflects substantial progress in cancer care. Moving forward, continued investment in cancer prevention, early detection, and treatment is crucial to further improve outcomes and reduce the burden of cancer on individuals and society.

Source:

Shelton, Jon, Ewa Zotow, Lesley Smith, Shane A. Johnson, Catherine S. Thomson, Amar Ahmad, Lars Murdock, Diana Nagarwalla, and David Forman. “25 Year Trends in Cancer Incidence and Mortality among Adults Aged 35-69 Years in the UK, 1993-2018: Retrospective Secondary Analysis.” BMJ (Clinical Research Ed.) 384 (March 13, 2024): e076962. https://doi.org/10.1136/bmj-2023-076962.

 

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    ByAlex Strauss

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    ByAlex Strauss

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    ByAlex Strauss

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…